{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T16:07:35Z","timestamp":1767974855089,"version":"3.49.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"6","funder":[{"name":"Novartis Pharma AG"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1007\/s12325-015-0220-6","type":"journal-article","created":{"date-parts":[[2015,6,24]],"date-time":"2015-06-24T07:42:14Z","timestamp":1435131734000},"page":"496-509","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Daptomycin in the Clinical Setting: 8-Year Experience with Gram-positive Bacterial Infections from the EU-CORESM Registry"],"prefix":"10.1007","volume":"32","author":[{"given":"Armando","family":"Gonzalez-Ruiz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panayiotis","family":"Gargalianos-Kakolyris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Artur","family":"Timerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jayanta","family":"Sarma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00edctor","family":"Jos\u00e9 Gonz\u00e1lez Ramallo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamel","family":"Bouylout","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe","family":"Trostmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rashidkhan","family":"Pathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1896-9736","authenticated-orcid":false,"given":"Kamal","family":"Hamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,6,25]]},"reference":[{"issue":"3","key":"220_CR1","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/jac\/dkh546","volume":"55","author":"JN Steenbergen","year":"2005","unstructured":"Steenbergen JN, Alder J, Thorne GM, Tally FP. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J Antimicrob Chemother. 2005;55(3):283\u20138.","journal-title":"J Antimicrob Chemother."},{"key":"220_CR2","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/1471-2334-10-151","volume":"10","author":"HN Shen","year":"2010","unstructured":"Shen HN, Lu CL. Skin and soft tissue infections in hospitalized and critically ill patients: a nationwide population-based study. BMC Infect Dis. 2010;10:151.","journal-title":"BMC Infect Dis"},{"issue":"3","key":"220_CR3","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1128\/CMR.00081-09","volume":"23","author":"MZ David","year":"2010","unstructured":"David MZ, Daum RS. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin Microbiol Rev. 2010;23(3):616\u201387.","journal-title":"Clin Microbiol Rev"},{"key":"220_CR4","doi-asserted-by":"crossref","unstructured":"Dryden MS. Complicated skin and soft tissue infection. J Antimicrob Chemother. 2010;65 Suppl 3:iii35\u201344.","DOI":"10.1093\/jac\/dkq302"},{"key":"220_CR5","unstructured":"European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2012. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC; 2013."},{"issue":"12","key":"220_CR6","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1086\/518452","volume":"44","author":"S Deresinski","year":"2007","unstructured":"Deresinski S. Counterpoint: vancomycin and Staphylococcus aureus\u2013an antibiotic enters obsolescence. Clin Infect Diseases. 2007;44(12):1543\u20138.","journal-title":"Clin Infect Diseases"},{"issue":"12","key":"220_CR7","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.4065\/mcp.2011.0514","volume":"86","author":"AM Rivera","year":"2011","unstructured":"Rivera AM, Boucher HW. Current concepts in antimicrobial therapy against select gram-positive organisms: methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci, and vancomycin-resistant enterococci. Mayo Clin Proc. 2011;86(12):1230\u201343.","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"220_CR8","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/infdis\/jir275","volume":"204","author":"TL Holland","year":"2011","unstructured":"Holland TL, Fowler VG Jr. Vancomycin minimum inhibitory concentration and outcome in patients with Staphylococcus aureus bacteremia: pearl or pellet? J Infect Dis. 2011;204(3):329\u201331.","journal-title":"J Infect Dis"},{"issue":"3","key":"220_CR9","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1093\/infdis\/jir270","volume":"204","author":"NE Holmes","year":"2011","unstructured":"Holmes NE, Turnidge JD, Munckhof WJ, et al. Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. J Infect Dis. 2011;204(3):340\u20137.","journal-title":"J Infect Dis"},{"issue":"4","key":"220_CR10","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s00134-011-2130-7","volume":"37","author":"EY Choi","year":"2011","unstructured":"Choi EY, Huh JW, Lim CM, et al. Relationship between the MIC of vancomycin and clinical outcome in patients with MRSA nosocomial pneumonia. Intensive Care Med. 2011;37(4):639\u201347.","journal-title":"Intensive Care Med"},{"key":"220_CR11","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1146\/annurev.micro.56.012302.160806","volume":"56","author":"TR Walsh","year":"2002","unstructured":"Walsh TR, Howe RA. The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus. Annu Rev Microbiol. 2002;56:657\u201375.","journal-title":"Annu Rev Microbiol"},{"issue":"Suppl 2","key":"220_CR12","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1007\/BF02561665","volume":"27","author":"WC Albrich","year":"1999","unstructured":"Albrich WC, Angstwurm M, Bader L, Gartner R. Drug resistance in intensive care units. Infection. 1999;27(Suppl 2):S19\u201323.","journal-title":"Infection"},{"issue":"3","key":"220_CR13","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1046\/j.1532-5415.2001.4930270.x","volume":"49","author":"WE Trick","year":"2001","unstructured":"Trick WE, Weinstein RA, DeMarais PL, et al. Colonization of skilled-care facility residents with antimicrobial-resistant pathogens. J Am Geriatr Soc. 2001;49(3):270\u20136.","journal-title":"J Am Geriatr Soc"},{"issue":"9","key":"220_CR14","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.3201\/eid1009.040069","volume":"10","author":"EW Tiemersma","year":"2004","unstructured":"Tiemersma EW, Bronzwaer SL, Lyytikainen O, et al. Methicillin-resistant Staphylococcus aureus in Europe, 1999\u20132002. Emerg Infect Dis. 2004;10(9):1627\u201334.","journal-title":"Emerg Infect Dis"},{"key":"220_CR15","unstructured":"Novartis Europharm Ltd. Cubicin\u00ae (daptomycin) summary of product characteristics. 2012."},{"issue":"12","key":"220_CR16","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1086\/420818","volume":"38","author":"RD Arbeit","year":"2004","unstructured":"Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis. 2004;38(12):1673\u201381.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"220_CR17","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1592\/phco.27.12.1611","volume":"27","author":"SL Davis","year":"2007","unstructured":"Davis SL, McKinnon PS, Hall LM, et al. Daptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomes. Pharmacotherapy. 2007;27(12):1611\u20138.","journal-title":"Pharmacotherapy."},{"issue":"3","key":"220_CR18","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ijantimicag.2013.05.005","volume":"42","author":"IM Gould","year":"2013","unstructured":"Gould IM, Miro JM, Rybak MJ. Daptomycin: the role of high-dose and combination therapy for Gram-positive infections. Int J Antimicrob Agents. 2013;42(3):202\u201310.","journal-title":"Int J Antimicrob Agents"},{"key":"220_CR19","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4137\/CMRT.S9283","volume":"6","author":"T Kelesidis","year":"2014","unstructured":"Kelesidis T. Pharmacological agents for the treatment of skin and soft tissue infections: what is the role for daptomycin? Clin Med Rev Ther. 2014;6:7\u201312.","journal-title":"Clin Med Rev Ther."},{"issue":"4","key":"220_CR20","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1093\/jac\/dkq528","volume":"66","author":"A Gonzalez-Ruiz","year":"2011","unstructured":"Gonzalez-Ruiz A, Beiras-Fernandez A, Lehmkuhl H, Seaton RA, Loeffler J, Chaves RL. Clinical experience with daptomycin in Europe: the first 2.5 years. J Antimicrob Chemother. 2011;66(4):912\u20139.","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"220_CR21","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa053783","volume":"355","author":"VG Fowler Jr","year":"2006","unstructured":"Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355(7):653\u201365.","journal-title":"N Engl J Med."},{"issue":"5","key":"220_CR22","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.ijantimicag.2013.01.019","volume":"41","author":"RA Seaton","year":"2013","unstructured":"Seaton RA, Gonzalez-Ramallo VJ, Prisco V, et al. Daptomycin for outpatient parenteral antibiotic therapy: a European registry experience. Int J Antimicrob Agents. 2013;41(5):468\u201372.","journal-title":"Int J Antimicrob Agents"},{"issue":"11","key":"220_CR23","doi-asserted-by":"crossref","first-page":"5626","DOI":"10.1128\/AAC.00038-12","volume":"56","author":"I Byren","year":"2012","unstructured":"Byren I, Rege S, Campanaro E, et al. Randomized controlled trial of the safety and efficacy of Daptomycin versus standard-of-care therapy for management of patients with osteomyelitis associated with prosthetic devices undergoing two-stage revision arthroplasty. Antimicrob Agents Chemother. 2012;56(11):5626\u201332.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"220_CR24","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1093\/jac\/dks467","volume":"68","author":"PM Dohmen","year":"2013","unstructured":"Dohmen PM, Guleri A, Capone A, et al. Daptomycin for the treatment of infective endocarditis: results from a European registry. J Antimicrob Chemother. 2013;68(4):936\u201342.","journal-title":"J Antimicrob Chemother."},{"issue":"6","key":"220_CR25","first-page":"183","volume":"1","author":"JS Bubalo","year":"2013","unstructured":"Bubalo JS, Kullar R, Maziarz RT. A pilot study of the efficacy and safety of empiric daptomycin therapy in oncology patients with fever and severe neutropenia. Ther Adv Infect Dis. 2013;1(6):183\u201390.","journal-title":"Ther Adv Infect Dis."},{"issue":"14","key":"220_CR26","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1517\/14656566.2013.820276","volume":"14","author":"JM Rybak","year":"2013","unstructured":"Rybak JM, Barber KE, Rybak MJ. Current and prospective treatments for multidrug-resistant gram-positive infections. Expert Opin Pharmacother. 2013;14(14):1919\u201332.","journal-title":"Expert Opin Pharmacother"},{"issue":"12","key":"220_CR27","doi-asserted-by":"crossref","first-page":"6213","DOI":"10.1128\/AAC.01563-13","volume":"57","author":"M Carugati","year":"2013","unstructured":"Carugati M, Bayer AS, Miro JM, et al. High-dose daptomycin therapy for left-sided infective endocarditis: a prospective study from the international collaboration on endocarditis. Antimicrob Agents Chemother. 2013;57(12):6213\u201322.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"220_CR28","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40121-014-0035-9","volume":"3","author":"L Legout","year":"2014","unstructured":"Legout L, D\u2019Elia P, Sarraz-Bournet B, et al. Tolerability of high doses of daptomycin in the treatment of prosthetic vascular graft infection: a retrospective study. Infect Dis Ther. 2014;3(2):215\u201323.","journal-title":"Infect Dis Ther."},{"issue":"9","key":"220_CR29","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1016\/j.clinthera.2009.09.012","volume":"31","author":"G Sakoulas","year":"2009","unstructured":"Sakoulas G, Brown J, Lamp KC, Friedrich LV, Lindfield KC. Clinical outcomes of patients receiving daptomycin for the treatment of Staphylococcus aureus infections and assessment of clinical factors for daptomycin failure: a retrospective cohort study utilizing the Cubicin Outcomes Registry and Experience. Clin Ther. 2009;31(9):1936\u201345.","journal-title":"Clin Ther"},{"issue":"5","key":"220_CR30","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.ijantimicag.2008.01.006","volume":"31","author":"RA Seaton","year":"2008","unstructured":"Seaton RA, Macconnachie AA. Experience with daptomycin in an infectious diseases service over 1\u00a0year: utility in an outpatient parenteral antibiotic programme. Int J Antimicrob Agents. 2008;31(5):492\u20137.","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"220_CR31","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1093\/cid\/ciu296","volume":"59","author":"DL Stevens","year":"2014","unstructured":"Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10\u201352.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"220_CR32","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1093\/jac\/dkr450","volume":"67","author":"FK Gould","year":"2012","unstructured":"Gould FK, Denning DW, Elliott TS, et al. Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother. 2012;67(2):269\u201389.","journal-title":"J Antimicrob Chemother."},{"issue":"12","key":"220_CR33","doi-asserted-by":"crossref","first-page":"5475","DOI":"10.1128\/AAC.00168-11","volume":"55","author":"JA Bosso","year":"2011","unstructured":"Bosso JA, Nappi J, Rudisill C, et al. Relationship between vancomycin trough concentrations and nephrotoxicity: a prospective multicenter trial. Antimicrob Agents Chemother. 2011;55(12):5475\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"220_CR34","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1086\/600884","volume":"49","author":"TP Lodise","year":"2009","unstructured":"Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis. 2009;49(4):507\u201314.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"220_CR35","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ijantimicag.2012.12.008","volume":"41","author":"S Rege","year":"2013","unstructured":"Rege S, Mohr J, Lamp KC, Yoon M, Lindfield KC. Safety of daptomycin in patients completing more than 14\u00a0days of therapy: results from the Cubicin(R) Outcomes Registry and experience. Int J Antimicrob Agents. 2013;41(5):421\u20135.","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"220_CR36","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1345\/aph.1R604","volume":"47","author":"TD Ramsey","year":"2013","unstructured":"Ramsey TD, Lau TT, Ensom MH. Serotonergic and adrenergic drug interactions associated with linezolid: a critical review and practical management approach. Ann Pharmacother. 2013;47(4):543\u201360.","journal-title":"Ann Pharmacother."},{"issue":"1","key":"220_CR37","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ijantimicag.2009.08.019","volume":"35","author":"M Lichterfeld","year":"2010","unstructured":"Lichterfeld M, Ferraro MJ, Davis BT. High-dose daptomycin for the treatment of endocarditis caused by Staphylococcus aureus with intermediate susceptibility to glycopeptides. Int J Antimicrob Agents. 2010;35(1):96.","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"220_CR38","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1128\/AAC.01291-10","volume":"55","author":"C Vidaillac","year":"2011","unstructured":"Vidaillac C, Steed ME, Rybak MJ. Impact of dose de-escalation and escalation on daptomycin\u2019s pharmacodynamics against clinical methicillin-resistant Staphylococcus aureus isolates in an in vitro model. Antimicrob Agents Chemother. 2011;55(5):2160\u20135.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"220_CR39","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.eimc.2008.09.003","volume":"27","author":"F Gudiol","year":"2009","unstructured":"Gudiol F, Aguado JM, Pascual A, et al. Consensus document for the treatment of bacteremia and endocarditis caused by methicillin-resistent Staphylococcus aureus. Sociedad Espanola de Enfermedades Infecciosas y Microbiologia Clinica. Enferm Infecc Microbiol Clin. 2009;27(2):105\u201315.","journal-title":"Enferm Infecc Microbiol Clin"},{"issue":"9","key":"220_CR40","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1128\/AAC.00526-13","volume":"57","author":"AM Casapao","year":"2013","unstructured":"Casapao AM, Kullar R, Davis SL, et al. Multicenter study of high-dose daptomycin for treatment of enterococcal infections. Antimicrob Agents Chemother. 2013;57(9):4190\u20136.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"220_CR41","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ijantimicag.2012.10.019","volume":"41","author":"CW Cheng","year":"2013","unstructured":"Cheng CW, Hsu PC, Yang CC, et al. Influence of early daptomycin therapy on treatment outcome of meticillin-resistant Staphylococcus aureus bacteraemia with high vancomycin minimum inhibitory concentrations. Int J Antimicrob Agents. 2013;41(3):293\u20134.","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"220_CR42","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1086\/600039","volume":"49","author":"DA Figueroa","year":"2009","unstructured":"Figueroa DA, Mangini E, Amodio-Groton M, et al. Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin Infect Dis. 2009;49(2):177\u201380.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"220_CR43","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1093\/jac\/dkr255","volume":"66","author":"EA King","year":"2011","unstructured":"King EA, McCoy D, Desai S, Nyirenda T, Bicking K. Vancomycin-resistant enterococcal bacteraemia and daptomycin: are higher doses necessary? J Antimicrob Chemother. 2011;66(9):2112\u20138.","journal-title":"J Antimicrob Chemother."},{"issue":"12","key":"220_CR44","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1093\/jac\/dkt294","volume":"68","author":"R Kullar","year":"2013","unstructured":"Kullar R, Casapao AM, Davis SL, et al. A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis. J Antimicrob Chemother. 2013;68(12):2921\u20136.","journal-title":"J Antimicrob Chemother."},{"issue":"6","key":"220_CR45","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1592\/phco.31.6.527","volume":"31","author":"R Kullar","year":"2011","unstructured":"Kullar R, Davis SL, Levine DP, et al. High-dose daptomycin for treatment of complicated gram-positive infections: a large, multicenter, retrospective study. Pharmacotherapy. 2011;31(6):527\u201336.","journal-title":"Pharmacotherapy."},{"key":"220_CR46","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1471-2334-13-66","volume":"13","author":"CC Lai","year":"2013","unstructured":"Lai CC, Sheng WH, Wang JT, et al. Safety and efficacy of high-dose daptomycin as salvage therapy for severe gram-positive bacterial sepsis in hospitalized adult patients. BMC Infect Dis. 2013;13:66.","journal-title":"BMC Infect Dis"},{"issue":"11","key":"220_CR47","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/cid\/cit112","volume":"56","author":"KP Murray","year":"2013","unstructured":"Murray KP, Zhao JJ, Davis SL, et al. Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration\u00a0>1\u00a0mg\/L: a matched cohort study. Clin Infect Dis. 2013;56(11):1562\u20139.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"220_CR48","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1086\/652767","volume":"50","author":"SM Bhavnani","year":"2010","unstructured":"Bhavnani SM, Rubino CM, Ambrose PG, Drusano GL. Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. Clin Infect Dis. 2010;50(12):1568\u201374.","journal-title":"Clin Infect Dis"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-015-0220-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T10:26:21Z","timestamp":1498213581000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-015-0220-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["220"],"URL":"https:\/\/doi.org\/10.1007\/s12325-015-0220-6","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6]]}}}